Globally, Prostate Cancer is the second most common type of cancer and the fifth leading cause of cancer-related death inmen, Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.PSA (Prostate Specific Antigen) has gained prominence as one of the most valuable tumor markers and is currently used forscreening,diagnosis and monitoring for prostate cancer.Due to highly invasive nature of biopsy, screening with PSA testing obviates avoidable biopsy in many cases, hence preferredby doctors as first line screening test in suspected prostate cancer casesThe generally accepted cut-off level is 4 ng/ml for likelihood of Prostate Cancer and further biopsy. However, there have beenpublished papers on use of 3 ng/ml as cut-off, which has been documented to be of higher significance in early diagnosis ofProstate Cancer.

Product Advantages:

High Accuracy

Easy Visual Interpretation

Convenient Procedure

Device, Buffer and Absorbent Tip

Fast Results in 5 Minutes3 in 1 Integrated